Vis enkel innførsel

dc.contributor.authorMehl, Arne
dc.contributor.authorHarthug, Stig
dc.contributor.authorLydersen, Stian
dc.contributor.authorPaulsen, Julie
dc.contributor.authorÅsvold, Bjørn Olav
dc.contributor.authorSolligård, Erik
dc.contributor.authorDamås, Jan Kristian
dc.contributor.authorEdna, Tom-Harald
dc.date.accessioned2015-03-05T07:56:28Z
dc.date.accessioned2015-03-26T14:03:52Z
dc.date.available2015-03-05T07:56:28Z
dc.date.available2015-03-26T14:03:52Z
dc.date.issued2014
dc.identifier.citationEuropean Journal of Clinical Microbiology and Infectious Diseases 2014nb_NO
dc.identifier.issn1435-4373
dc.identifier.urihttp://hdl.handle.net/11250/280276
dc.descriptionThis article is published with open access at Springerlink.comnb_NO
dc.description.abstractn several studies on patients with bloodstream infection (BSI), prior use of statins has been associated with improved survival. Gram-positive and Gram-negative bacteria alert the innate immune system in different ways. We, therefore, studied whether the relation between prior statin use and 90-day total mortality differed between Gram-positive and Gram-negative BSI. We conducted a prospective observational cohort study of 1,408 adults with BSI admitted to Levanger Hospital between January 1, 2002, and December 31, 2011. Data on the use of statins and other medications at admission, comorbidities, functional status, treatment, and outcome were obtained from the patients’ hospital records. The relation of statin use with 90-day mortality differed between Gram-negative and Gram-positive BSI (p-value for interaction 0.01). Among patients with Gram-negative BSI, statin users had significantly lower 90-day total mortality [odds ratio (OR) 0.42, 95 % confidence interval (CI) 0.23–0.75, p = 0.003]. The association remained essentially unchanged after adjusting for the effect of sex, age, functional status before the infection, and underlying diseases that were considered confounders (adjusted OR 0.38, 95 % CI 0.20–0.72, p = 0.003). A similar analysis of patients with Gram-positive BSI showed no association of statin use with mortality (adjusted OR 1.22, 95 % CI 0.69–2.17, p = 0.49). The present study suggests that prior statin use is associated with a lower 90-day total mortality in Gram-negative BSI, but not in Gram-positive BSI.nb_NO
dc.language.isoengnb_NO
dc.publisherSpringer Berlin Heidelbergnb_NO
dc.titlePrior statin use and 90-day mortality in Gram-negative and Gram-positive bloodstream infection: a prospective observational studynb_NO
dc.typeJournal articlenb_NO
dc.typePeer revieweden_GB
dc.date.updated2015-03-05T07:56:28Z
dc.subject.nsiVDP::Medisinske fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Medisinsk mikrobiologi : 715nb_NO
dc.subject.nsiVDP::Midical sciences: 700::Basic medical, dental and veterinary sciences: 710::Medical microbiology: 715nb_NO
dc.source.pagenumber609-617nb_NO
dc.source.volume34nb_NO
dc.source.journalEuropean Journal of Clinical Microbiology and Infectious Diseasesnb_NO
dc.source.issue3nb_NO
dc.identifier.doi10.1007/s10096-014-2269-6
dc.identifier.cristin1190880
dc.relation.projectNorges forskningsråd: 223255nb_NO


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel